FDA Drafts Study Guides to Help Generic Drugs Prove Equivalence
Published Date: 11/20/2026
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like brand-name ones. If you’re in the drug business, these guides show you exactly what the FDA expects, making the approval process smoother and faster. You’ve got until January 19, 2027, to send your feedback before these guides become final—saving time and possibly money down the road!
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
New draft guidances for specific drugs
FDA posted new draft product-specific guidances that give product-specific recommendations on designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The new drafts apply to products containing Aficamten; Barium sulfate; Berotralstat dihydrochloride; Bumetanide; Delgocitinib; Dihydroergotamine mesylate; Ethinyl estradiol; Norethindrone acetate; Imlunestrant tosylate; Lamotrigine; Nerandomilast; Orforglipron; Paltusotine hydrochloride; Remibrutinib; Sepiapterin; and Zongertinib.
Revised draft guidances for listed drugs
FDA posted revised draft product-specific guidances with recommendations on BE study design for ANDAs for products containing Albuterol sulfate; Azathioprine; Betaxolol hydrochloride; Bupropion hydrochloride; Dextromethorphan hydrobromide; Carbinoxamine maleate; Estrogens, conjugated; Gabapentin enacarbil; Ixazomib citrate; Lanreotide acetate; Lenvatinib mesylate; Naltrexone; Nitroglycerin; Pyridostigmine bromide; and Trifarotene.
60‑day public comment deadline (Jan 19, 2027)
Stakeholders may submit electronic or written comments on these draft guidances and must submit them by January 19, 2027 for FDA to consider them before it begins work on the final versions. Comments submitted to https://www.regulations.gov will be posted publicly unless submitted as written/paper confidential submissions following FDA's instructions.
Guidances are non‑binding; alternatives allowed
FDA states that these draft guidances, when finalized, will represent the Agency's current thinking but do not establish any rights and are not binding. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
FDA will consider cost comments under EO 14192
FDA will consider comments on costs or cost savings the guidance may generate as it develops final guidances, consistent with Executive Order 14192. Stakeholders can submit cost or cost‑savings information for FDA's consideration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-14967, Requirements for Additional Traceability Records for Certain Foods: Compliance Date Extension
The FDA is giving food businesses more time—30 extra months—to follow new rules about tracking certain foods. This means the deadline moves from January 2026 to July 2028, helping companies get ready without rushing. If you’re involved in food production or sales, this extension gives you a breather to avoid costly mistakes and meet the new tracking requirements smoothly.
Previous / Next Documents
Previous: 2026-23687, Board of Overseers of the Malcolm Baldrige National Quality Award
The Board of Overseers for the Malcolm Baldrige National Quality Award is meeting on December 10, 2026, to review and improve the award program that helps U.S. businesses and organizations get better at what they do. This open, virtual meeting affects companies and nonprofits aiming for top-quality performance and offers a chance to shape future improvements—no costs or deadlines for attendees. It’s a big deal for anyone interested in excellence across industries like healthcare, education, and manufacturing.
Next: 2026-23693, Submission for OMB Review; Comment Request
The Department of Agriculture wants your feedback on a form they use to help meat and poultry businesses grow. They’re checking if the questions make sense and don’t take too much time. If you’re involved in meat or poultry processing, you can comment by December 21, 2026, to help shape this program and keep things running smoothly.